ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
AbCellera Biologics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Licensing and royalty revenue | $46.92M | $1.05M | $969.00K | $696.00K | $20.78M | – | – | 62.5% | +4372.8% |
| Research fees | $27.21M | $26.28M | $35.56M | $40.80M | $19.08M | $19.85M | $11.61M | 36.2% | +3.5% |
| Milestone payments | $1.00M | $1.50M | $1.50M | $900.00K | $8.00M | $15.00M | – | 1.3% | -33.3% |
| Royalty revenue | – | $0 | $0 | $443.03M | $327.35M | $198.31M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Canada | $64.00M | $26.20M | $36.00M | $484.20M | $353.40M | – | – | 85.2% | +144.3% |
| United States | $11.10M | $2.70M | $2.00M | $1.20M | $21.80M | – | – | 14.8% | +311.1% |
From the segment and revenue-disaggregation notes of AbCellera Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.